Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2017’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)

The report reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics and enlists all their major and minor projects

The report assesses Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

advanceCor GmbH

Akcea Therapeutics Inc

Amarantus Bioscience Holdings Inc

AnGes MG Inc

Arena Pharmaceuticals Inc

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athera Biotechnologies AB

Bayer AG

Biscayne Pharmaceuticals Inc

Capricor Therapeutics Inc

Cardiome Pharma Corp

CardioVascular BioTherapeutics Inc

Cerenis Therapeutics Holding SA

CSL Ltd

Esperion Therapeutics Inc

Gilead Sciences Inc

HitGen LTD

Human Stem Cells Institute

Japan Tobacco Inc

Juventas Therapeutics Inc

Lee's Pharmaceutical Holdings Ltd

LipimetiX Development Inc

Lonestar Heart Inc

MedImmune LLC

Merck & Co Inc

Nuo Therapeutics Inc

Pfizer Inc

Pharmahungary Group

Proteon Therapeutics Inc

Resverlogix Corp

Tasly Pharmaceutical Group Co Ltd

The Medicines Company

Verseon Corp

VESSL Therapeutics Ltd

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 29

advanceCor GmbH 29

Akcea Therapeutics Inc 29

Amarantus Bioscience Holdings Inc 30

AnGes MG Inc 30

Arena Pharmaceuticals Inc 31

Ascendia Pharmaceuticals LLC 31

AstraZeneca Plc 32

Athera Biotechnologies AB 32

Bayer AG 33

Biscayne Pharmaceuticals Inc 33

Capricor Therapeutics Inc 34

Cardiome Pharma Corp 34

CardioVascular BioTherapeutics Inc 35

Cerenis Therapeutics Holding SA 35

CSL Ltd 36

Esperion Therapeutics Inc 36

Gilead Sciences Inc 37

HitGen LTD 37

Human Stem Cells Institute 38

Japan Tobacco Inc 38

Juventas Therapeutics Inc 39

Lee's Pharmaceutical Holdings Ltd 39

LipimetiX Development Inc 40

Lonestar Heart Inc 40

MedImmune LLC 41

Merck & Co Inc 41

Nuo Therapeutics Inc 42

Pfizer Inc 42

Pharmahungary Group 43

Proteon Therapeutics Inc 43

Resverlogix Corp 44

Tasly Pharmaceutical Group Co Ltd 44

The Medicines Company 45

Verseon Corp 45

VESSL Therapeutics Ltd 46

ViroMed Co Ltd 46

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 47

4-WF - Drug Profile 47

AEM-28 - Drug Profile 48

AEM-2802 - Drug Profile 50

ALD-201 - Drug Profile 51

alprostadil - Drug Profile 53

AMRS-001 - Drug Profile 54

anacetrapib - Drug Profile 63

apabetalone - Drug Profile 65

AZD-5069 - Drug Profile 77

AZD-5718 - Drug Profile 79

beperminogene perplasmid - Drug Profile 80

Biologics for Acute Coronary Syndrome - Drug Profile 86

BIS-5409 - Drug Profile 87

bivalirudin - Drug Profile 88

cangrelor tetrasodium - Drug Profile 89

CAP-1002 - Drug Profile 93

CAP-2003 - Drug Profile 99

CER-001 - Drug Profile 101

clopidogrel bisulphate - Drug Profile 105

COR-2 - Drug Profile 106

Cryocell - Drug Profile 107

CSL-112 - Drug Profile 108

CVBT-141H - Drug Profile 110

dalcetrapib - Drug Profile 111

Gemacell - Drug Profile 115

Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile 116

IONIS-APOARX - Drug Profile 117

JVS-100 - Drug Profile 120

MEDI-6012 - Drug Profile 125

MultiGeneAngio - Drug Profile 128

MZ-004 - Drug Profile 129

Neovasculgen - Drug Profile 131

PC-mAb - Drug Profile 132

PF-06282999 - Drug Profile 135

PMC-6 - Drug Profile 136

PR-15 - Drug Profile 137

Proteins for Ischemic Heart Disease - Drug Profile 139

ranolazine ER - Drug Profile 140

Recombinant Protein for Cardiovascular Diseases - Drug Profile 143

Rejuveinix - Drug Profile 144

rivaroxaban - Drug Profile 145

Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 161

Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 162

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 163

temanogrel hydrochloride - Drug Profile 165

tirofiban hydrochloride - Drug Profile 167

TSL-0202 - Drug Profile 168

vericiguat - Drug Profile 169

VM-202 - Drug Profile 171

vonapanitase - Drug Profile 175

ZK-001 - Drug Profile 180

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 182

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 188

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 190

Featured News & Press Releases 190

Appendix 202

Methodology 202

Coverage 202

Secondary Research 202

Primary Research 202

Expert Panel Validation 202

Contact Us 202

Disclaimer 203

List of Tables

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by advanceCor GmbH, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Akcea Therapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by AnGes MG Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Arena Pharmaceuticals Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Ascendia Pharmaceuticals LLC, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by AstraZeneca Plc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Athera Biotechnologies AB, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Bayer AG, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

1`

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Cardiome Pharma Corp, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CardioVascular BioTherapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Cerenis Therapeutics Holding SA, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CSL Ltd, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Esperion Therapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Gilead Sciences Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by HitGen LTD, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Human Stem Cells Institute, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Japan Tobacco Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Juventas Therapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by LipimetiX Development Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Lonestar Heart Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by MedImmune LLC, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Merck & Co Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Nuo Therapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Pfizer Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Pharmahungary Group, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Proteon Therapeutics Inc, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Resverlogix Corp, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by The Medicines Company, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Verseon Corp, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by VESSL Therapeutics Ltd, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by ViroMed Co Ltd, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared